There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report), Twist......

In a report released today, Uy Ear from Mizuho Securities upgraded Sarepta Therapeutics to a Buy, with a price target of $26.00. The company’s shar......

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report) and Sarepta Thera......

RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $16.00. The company’s share......

H.C. Wainwright analyst Mitchell Kapoor reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $5.00. The company’s share......

Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular dystrophy......

Sarepta Therapeutics Inc. ( ($SRPT) ) has released its Q3 earnings. Here is a breakdown of the information Sarepta Therapeutics Inc. presented to i......

Sarepta Therapeutics Inc. (($SRPT)) announced an update on their ongoing clinical study. Study Overview: The study titled ‘A Two-Part, Open-Label S......